COMPANY PROFILE

Fulmz AI

Explore full profile

Fulmz AI is a pharmaceutical technology developer

Guangzhou, ChinaFounded 2015Biotech & Life Sciences

Valuation $50–100M Last recorded · 2022

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Fulmz AI

Fermion is a pioneering company in the field of AI-driven drug discovery, focusing on the rapid design, large-scale screening, and precise calculations of small molecule drugs. By integrating advanced AI technology with traditional drug discovery pathways, Fermion leverages its proprietary Drug Studio AI platform to generate molecules with optimal parameters. The company specializes in developing innovative drug therapies targeting novel areas in neurology and autoimmune diseases. Fermion's business model revolves around progressing these small molecule drugs through Phases 1 and 2 clinical trials, thereby increasing the success rate of drug discovery. The company's clientele primarily includes pharmaceutical firms and research institutions looking for cutting-edge solutions in drug development. Fermion operates in the biotechnology and pharmaceutical markets, making money through partnerships, licensing agreements, and milestone payments tied to the success of its drug programs.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2015
Headquarters: Guangzhou, China
Open positions: None listed
Dealroom signal: 17.0/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Drug Development, Biotech and Pharma, Techbio, Hard Tech, DT and LS, science-based
Links: Website

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES B✓Equity / VC	Jul 2022	$14M	$55M	Panda Capital · Zhengxuan Investment · Xingyun.cn · Challenjers	↗
SEEDEquity / VC	Jun 2019	—	—	Challenjers · Panda Capital	—

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Fulmz AI website traffic

Latest recorded traffic for Fulmz AI is 210 monthly website visits, down 61.8% over the last three months.

Latest monthly visits210 3-month web change-61.8%

Monthly website visitsFeb 2020–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ABAliveX BiotechApplication of artificial intelligence, multi-omics data, and digital disease models to enable the next era of target & biomarker R&D	Jing'an District, China	Operational	18	—	—
BRBrainify.AIBrainify.AI is an AI/ML electroencephalography (EEG) biomarker platform for novel treatment development aimed at depression that increases the likelihood of new drug approval by 80% and reduces R&D costs by $1.5B	New York City, United States	Operational
NENetTargetsAI-enhanced systems biology platform for drug discovery	Daejeon, South Korea	Operational
COConcertoCareTech-enabled, value-based provider of at-home, comprehensive care for seniors and other adults	New York City, United States	Operational
CTCeleris TherapeuticsPredicting biomolecular interactions and designing drugs for incurable diseases	Graz, Austria	Operational
TRTrails.aiAI-powered platform optimizing clinical trial protocols	San Diego, United States	Acquired
EXExogeneBiotechnology company accelerating target and TCR discovery for cancer cell therapies using AI-enabled TCR-antigen screening	Oxford, United Kingdom	Operational
CBCharacter BiosciencesBiopharmaceutical research and development company	Clifton, United States	Operational